City of Hope and TGen research reveals potential cause of aggressive leukemia

Leukemia & Lymphoma Society renamed Blood Cancer United

The Leukemia & Lymphoma Society is becoming Blood Cancer United on August 28 in advance of Blood Cancer Awareness Month in September.

August 01, 2025

Vol.51 No.30

Clinical Roundup

IGRT shows no reduction in serious infections for patients with CLL

Regular treatment with immunoglobulin replacement therapy in patients with chronic lymphocytic leukemia was not associated with a reduced risk of serious infections requiring hospitalization, according to a study published in Blood Advances.

August 01, 2025

Vol.51 No.30

City of Hope brings evidence-based approaches to integrative oncology

The landscape of cancer care is evolving rapidly, with growing recognition that optimal patient outcomes require a whole-person care approach that goes beyond cytotoxic and targeted therapies.

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

A study published today by researchers at the Translational Genomics Research Institute, part of City of Hope, and clinician-scientists at Baylor Scott & White Research Institute revealed a potential new therapeutic strategy for fighting lung cancer that harnesses one of the body’s immune cells, natural killer cells.

July 25, 2025

Vol.51 No.29

Imaging’s ride to the bottom in clinical trials—and why it matters now

In cancer care, imaging has become a marvel of modern medicine. Advances in scanner technology, reconstruction algorithms, contrast agents, and diagnostic protocols have radically improved our ability to detect, track, and understand disease. Clinically, imaging is fast, accurate, and central to decision-making.

July 18, 2025

Vol.51 No.28

By Jeff Sorenson

Unraveling connections between diabetes and cancer: Insights from metabolism research at City of Hope

The intersection of diabetes, obesity and cancer represents an important and underappreciated challenge in medicine. Apart from smoking, overweight is now the leading modifiable risk factor for cancer. With the global epidemic of overweight and diabetes driving cancer incidence across multiple organ sites, understanding the metabolic underpinnings of this relationship has never been more critical.

July 11, 2025

Vol.51 No.27

By Charles Brenner